Xin Lang Cai Jing·2025-12-05 08:22Core Viewpoint - Shanghai Pharmaceuticals announced the termination of the cooperation agreement related to the X842 project with Shengnuo Biotech, which will not significantly impact the company's financial and operational performance [1] Group 1 - In 2021, Shanghai Pharmaceuticals' wholly-owned subsidiary, Shanghai Pharmaceuticals Xinyi, signed an original cooperation agreement with Guizhou Shengnuo and Jiangsu Shengnuo for the X842 project, granting exclusive production and sales rights [1] - On November 18, 2025, Shanghai Pharmaceuticals Xinyi and Shengnuo Biotech signed a termination agreement, which became effective upon the receipt of a refund of 110 million yuan [1] - The original cooperation agreement automatically terminated on December 5, 2025, after the receipt of the refund [1]